Table 4 Multivariate analysis for progression free survival and overall survival.

From: Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP

 

Progression-free survival

Overall survival

HR

95% CI

 

HR

95% CI

 

Lung met.

1.22

[0.80–1.87]

p = 0.35

1.38

[0.88–2.18]

p = 0.17

Lymph-node met.

0.99

[0.69–1.42]

p = 0.97

1.25

[0.86–1.81]

p = 0.25

Bone met.

1.62

[0.88–2.99]

p = 0.12

1.69

[0.92–3.08]

p = 0.09

Liver met.

0.93

[0.63–1.36]

p = 0.69

1.07

[0.71–1.61]

p = 0.74

Leucocytes > 10

1.20

[0.83–1.75]

p = 0.33

1.54

[1.04–2.26]

p = 0.03

LDH > ULN

1.62

[1.09–2.39]

p = 0.02

1.26

[0.86–1.85]

p = 0.23

Age > 65

1.10

[0.75–1.60]

p = 0.64

1.00

[0.68–1.47]

p = 0.99

WHO PS 1–2

1.22

[0.85–1.74]

p = 0.29

1.67

[1.13–2.46]

p = 0.01

Gender (male)

1.14

[0.78–1.66]

p = 0.49

1.19

[0.81–1.74]

p = 0.38

No of met sites > 2

1.14

[0.78–1.66]

p = 0.49

1.12

[0.76–1.66]

p = 0.58

  1. Bold values indicate statistical significance p value <0.05.
  2. The tables demonstrate the results of the multivariate analysis for the progression free survival and overall survival.
Back to article page